Table 1 Basic characteristics of included studies
From: A systematic review and meta-analysis of circulating serum and plasma microRNAs in TB diagnosis
Authors | Year | Country | Sample used | Patient Characteristics | Diagnosis | Screening method | Validation method | Biomarker utility | miRNA profile | Labeling for RF plot | Group definition for RF plot | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | Male/Female | Age | Cases | Male/Female | Age | |||||||||||
Abd-El-Fattah et al., | 2013 | Mexico | Serum | 37 HC | 21/16 | 50.1 ± 14.2 | 29 PTB | 17/12 | 47.7 ± 9.8 | TST |  | qRT-PCR | HC vs. PTB | miR-197↑ | A | HC vs. TB |
Carranza C et al., | 2021 | North Western China | Serum (Exosomes) | 15 HC | 10/5 | 45 (27–61) | 24 DR-TB | 18/11 | 43.5 (19–77) | PTB: Confirmed diagnosis of TB and were under Directly Observed Therapy | TaqMan RT-qPCR | TaqMan Advanced miRNA assays | HC vs. DR-TB | miR-197-3p↓ | B | HC vs. TB |
miR-223-3p↓ | C | HC vs. TB | ||||||||||||||
miR-let7e-5p↑ | D | HC vs. TB | ||||||||||||||
miRs(197-3p + let-7e-5p +223-3p) (Differential expression) | E | HC vs. TB | ||||||||||||||
HC vs. MDR-TB | miR-197-3p↓ | F | HC vs. TB | |||||||||||||
miR-223-3p ↓ | G | HC vs. TB | ||||||||||||||
miR-let7e-5p↑ | H | HC vs. TB | ||||||||||||||
miRs(197-3p + let-7e-5p +223-3p) (Differential expression) | I | HC vs. TB | ||||||||||||||
EN Ndzi et al., | 2019 | Cameroon | Plasma | 43 HC | 13/29 | 27 ± 7 | 84 PTB 35 LTB | PTB: 57/26 LTB: 8/27 | PTB: 33 ± 12 LTB: 34 ± 11 | PTB: Microscopy or culture (0, 2, 6) LTB: Positive QFT HC: Negative QFT | Database reported miRNAs | miRCURY LNA SYBR Green PCR kit (Qiagen, Maryland, USA) | HC vs. PTB | hsa-miR-29a-3p↑ | J | HC vs. TB |
hsa-miR-361-5p↑ | K | HC vs. TB | ||||||||||||||
LTB vs. PTB | hsa-miR-29a-3p↑ | L | LTB vs. TB | |||||||||||||
hsa-miR-361-5p↑ | M | LTB vs. TB | ||||||||||||||
Huihui Tu et al., | 2019 | China | Serum | 86 HC | 50/36 | 21-64 | 108 PTB | 66/42 | 18-72 | PTB: Diagnostic criteria of the Ministry of Health, China | Solexa sequencing | SYBR green qRT-PCR | HC vs. PTB | miR-17- 5p, miR-20b-5p, miR-423-5p↑ | N | HC vs. TB |
SE Barry et al., | 2018 | Egypt | Plasma | 100 HC | 57/43 | 35 (18-78) | 100 PTB | 58/42 | 43 (19-91) | PTB: Clinical and radiographic findings and sputum smear microscopy and mycobacterial culture HC: Interview and chest radiography | Plasma Focus miRNA PCR Panels (Exiqon) | qRT-PCR (Exiqon) | HC vs. PTB | miR-29a, miR-99b, miR-21, miR-146a, miR-652 (Differential expression) | O | HC vs. TB |
Yan Lv et al., | 2015 | China | Serum | 117 HC | 70/47 | 27.49 ± 8.80 | 124 PTB | 70/54 | 27.25 ± 8.99 | PTB: Typical TB clinical symptoms, bacterial culture, and imaging examinations |  | qRT-PCR | HC vs. PTB | miR-144↑ | P | HC vs. TB |
Xing Zhang et al. | 2013 | China | Serum | 88 HC | 65/23 | 48 (24–67) | 108 PTB | 73/35 | 45 (14–62) | PTB: clinical manifestations, bacterial culture, and radiographic findings |  | SYBR green qRT-PCR assay | HC vs. PTB | hsa-miR-378↓ | Q | HC vs. TB |
hsa-miR-483-5p↓ | R | HC vs. TB | ||||||||||||||
hsa-miR-22↓ | S | HC vs. TB | ||||||||||||||
hsa-miR-29c↓ | T | HC vs. TB | ||||||||||||||
hsa-miR-101↑ | U | HC vs. TB | ||||||||||||||
hsa-miR-320b↑ | V | HC vs. TB | ||||||||||||||
hsa-miR-378, hsa-miR-483-5p, hsa-miR-22, hsa-miR-29c, hsa-miR-101, hsa-miR-320b (Differential expression) | W | HC vs. TB | ||||||||||||||